Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 11
Submit an article Journal homepage
191
Views
8
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkinlymphoma

Elena CavalieriDivision of Hematology, Department of Cellular Biotechnologies and Hematology andCorrespondence[email protected]
,
Angela MatturroDivision of Hematology, Department of Cellular Biotechnologies and Hematology and
,
Giorgia AnnechiniDivision of Hematology, Department of Cellular Biotechnologies and Hematology and
,
Federico De AngelisDivision of Hematology, Department of Cellular Biotechnologies and Hematology and
,
Natalia FrattarelliDivision of Hematology, Department of Cellular Biotechnologies and Hematology and
,
Fabiana GentiliniDivision of Hematology, Department of Cellular Biotechnologies and Hematology and
,
Lavinia GrapulinDepartment of Radiotherapy, ‘Sapienza’ University, Rome, Italy
,
Mikael SaccoDivision of Hematology, Department of Cellular Biotechnologies and Hematology and
,
Fabio TorelliDivision of Hematology, Department of Cellular Biotechnologies and Hematology and
,
Marco VignettiDivision of Hematology, Department of Cellular Biotechnologies and Hematology and
,
Franco MandelliDivision of Hematology, Department of Cellular Biotechnologies and Hematology and
,
Robin FoàDivision of Hematology, Department of Cellular Biotechnologies and Hematology and
&
Alessandro PulsoniDivision of Hematology, Department of Cellular Biotechnologies and Hematology and
 show all
Pages 1803-1808 | Received 21 May 2009, Accepted 11 Aug 2009, Published online: 08 Oct 2009

References

  • Diehl V, Franklin J, Pfreundschuh M; German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386– 2395.
  • Diehl V, Franklin J, Paulus U. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood 2001;98:769– 771.
  • Diehl V, Fuchs M; GHSG. Will BEACOPP be the standard for high-risk Hodgkin's lymphoma patients in advanced stages? Transfus Apher Sci 2007;37:37– 41.
  • Diehl V, Sieber M, Ruffer U, et al BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 1997;8:143– 148.
  • Engel C, Leffler M, Schmitz S, Tesch H, Diehl V. Acute hematologic toxicity and practicability of dose intensified BEACOPP chemotherapy for advanced stages Hodgkin's disease. GHSG. Ann Oncol 2000;11:1105– 1114.
  • Lavoie JC, Connors JM, Philips GL, et al High dose chemotherapy and autologous stem cell transplant for primary refractory or relapsed Hodgkin's lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005;106:1473–1478.
  • Josting A. Autologous transplantation in relapsed and refractory Hodgkin's disease. Eur J Haematol 2005;66:141–145.
  • Anselmo AP, Cavalieri E, Meloni G, et al Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease. Haematologica 2002;87:507–511.
  • Schmitz N, Pfistner B, Sextro M. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065–2071.
  • Radman I, Basic N, Labar B, et al Long term results of conventional dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience). Ann Oncol 2002;13:1650–1655.
  • Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506–1514.
  • Josting A, Rueffer U, Franklin J. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96:1280–1286.
  • Abdel hamid T, El Zawahry HM, Khattab NA, et al Prognostic factors of Hodgkin's lymphoma and their impact on response to chemotherapy and survival. J Egypt Natl Canc Inst 2005;17:9–14.
  • Czyz J, Dziadziuszko R, Knopin'ska-Postuszuy W, et al Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 2004;15:1222–1230.
  • Morabito F, Stelitano C, Luminari S, et al The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). BMT 2006;37:283–288.
  • Josting A, Rudolph C, Mapara M, et al Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005;16:116–123.
  • Josting A, Wiedenmann S, Franklin J, et al Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;3:1–6.
  • Martínez C, Salamero O, Arenillas L, et al Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: Long-term outcome of 61 patients from a single institution. Leuk Lymphoma 2007;48:1968–1975.
  • Venkatesh H, Di Bella N, Flynn TP, et al Results of a phase trial of single agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma 2004;5:110–115.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.